Jim Scopa

Director, Chair of Audit Committee

2021 - Current

Director, Chair of Compensation Committee, Member of Audit Committee

2019

Member of Compensation and Audit Committees

Member of Investment Advisory Committee, Member of Advisory Board

2017

Advisor to Australian based venture capital firm with $330 million under management

Director, Chair of Audit Committee and Member of Compensation Committee

2015 - 2023

Member of Compensation Committee, Chair of Audit Committee

Director, Member of Audit Committee, Chair of Compensation Committee

2020 - 2023

Sold to Eli Lilly in August 2023 for $2.4 billion

Fellow, Distinguished Careers Institute ("DCI")

2017 - 2018

Focus on translational and regenerative medicine.

Managing Director -- Member of Investment Committee

2005 - 2017

Previously served on the boards of Semma Therapeutics sold to Vertex for $950 million, True North Therapeutics, sold to Bioverativ for $825 million in cash and future milestones, June 2017; Solasia K.K., IPO on Tokyo Stock Exchange March 2017 and fully exited June 2017; Nevro Corp. ("NVRO") Nasdaq IPO November 2014 and fully exited in August 2016; iPierian, Inc. sold to Bristol Myers Squibb for cash and milestones of $725 million in April 2014 ;TriVascular, Inc. Nasdaq IPO in April 2014 and sold to Endologix for $120 million in February 2016; Peplin, Inc.("PEP":ASX) sold to LEO Pharmaceuticals for $300 million in November 2009. Extensive experience on Compensation and Audit Committees for both public and private companies.

Partner and Managing Director

2002 - 2005

Co-Head Health Care Investment Banking; Member of Investment Committee of Thomas Weisel Health Care Venture Fund

Managing Director

1990 - 2002

Global Co-Head Health Care Investment Banking (1999-2002);Managing Director, Health Care Banking (1996-1999);Focus in Life Sciences and Medical Devices

Associate Investment Banking

1986 - 1989

Technology and Life Sciences Group